Navigation Links
Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
Date:3/15/2013

ock-based compensation expense
  • Net loss of $8 million to $10 million
  • Basic and diluted net loss of $0.20 to $0.25 per share
  • Year-end cash, cash equivalents and investments available for sale balance greater than $30 million
  • Revenues:"We expect development revenues in 2013 will be comprised of approximately $19 million in committed R&D funding and license fee revenues from existing collaborations, and we anticipate $6 million to $9 million in additional license fees, R&D funding, milestones and cost reimbursements," Rogers noted. 

    "We forecast the vast majority of 2013 commercial revenues to be based on existing collaboration agreements.  While it remains difficult to forecast commercial revenues due to uncertainties around product launch timing, the number of product lines that will include our flavor ingredients, and other factors, we are currently estimating 2013 commercial revenues to be approximately $6 million.

    "2013 should prove to be a transitional year for Senomyx as we implement our direct sales strategy," Rogers stated.  "While direct sales are not expected to yield significant results in 2013, our goal is for direct sales to be a key driver of meaningful commercial revenues in future years.

    Expenditures:"Looking at expenditures, as we consider our resource requirements over the next several years for R&D, G&A and Commercial Operations, excluding the cost of commercial revenues, we expect we will be able to manage our expenses to be generally in-line with our 2013 expense guidance range, subject to quarterly fluctuations and increases for inflation.
    With respect to the expanded commercial organization activities in support of our direct sales strategy, many of the functions will be handled by existing Senomyx personnel.  In other cases, such as supply chain and account management, we will add dedicated resources to support these functions.
    '/>"/>

    SOURCE Senomyx
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

    Related biology technology :

    1. Senomyx To Webcast Corporate Presentation At The 25th Annual ROTH Conference
    2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    3. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
    4. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
    5. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
    6. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
    7. WuXi PharmaTech Announces Third-Quarter 2011 Results
    8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
    9. Spherix Announces Third Quarter Financial Results
    10. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
    11. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/20/2014)... BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced four ... million and provides a good start to Q4.  The orders are ... and one in the Middle East . ... said Peter Bruijns , President & CEO. "Total bidding activity ... they have been for any complete year since the company has ...
    (Date:10/20/2014)... N.J. (PRWEB) October 20, 2014 ... the Sidney Kimmel Cancer Center at Thomas Jefferson ... , Through the Strategic Alliance Partnership program, ... OncLive will collaborate to raise awareness of the ... treatment, and other projects. Clinicians and other health ...
    (Date:10/19/2014)... October 20, 2014 OCTOBER ... Meeting (ABIM). ABIM will take place ... information about ABIM 2014 is now available ... Delegates representing companies and organizations from all ... obtain information on the latest products and ...
    (Date:10/19/2014)... The Asia-Pacific Speech Analytics market report ... with analysis and forecast of revenue. This market is ... $208 million by 2019, at a Compound Annual Growth ... Browse through the TOC of the Asia-Pacific Speech Analytics ... analysis provided. It also provides a glimpse of the ...
    Breaking Biology Technology:Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 2The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 4
    ... PARIS and LAUSANNE, Switzerland, September 7 ... Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical,group of ... prescription drugs that,target unmet medical needs, announced today ... granted an exclusive worldwide license to develop,and commercialise ...
    ... manufacture hydroxyapatite (HA) could be used to make stronger, ... University of Birmingham this week (7-10 September) presented work ... University, Edinburgh. Using Serratia bacteria, the ... surfaces such as titanium alloy, polypropylene, porous glass and ...
    ... Sept. 6 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq:, ... biotechnology company,focused on researching, developing, manufacturing and marketing,biopharmaceutical ... of,shareholders of 3SBio Inc. will be held on ... No.3 A1, Road 10, Shenyang Economy & Technology ...
    Cached Biology Technology:Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsen's Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent 2Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsen's Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent 3Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsen's Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent 4Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsen's Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent 53SBio Inc. to Hold 2009 Annual General Meeting on October 12, 2009 2
    (Date:10/15/2014)... increased resistance to bacterial pneumonia in female mice to ... , Females are naturally more resistant to respiratory infections ... shown that increased resistance to bacterial pneumonia in female ... 3 (NOS3). They also show that this enzyme is ... hormone estrogen. , The team, lead by Professor Lester ...
    (Date:10/15/2014)... Alt will be awarded the 44th Rosenstiel Award for ... his pioneering research exploring the mechanisms of genomic instability ... cells. Alt is the second alumnus to win the ... Prize in 2003. , Alt is the Charles A. ... Harvard Medical School and an investigator at the Howard ...
    (Date:10/14/2014)... N.C. – Like discriminating thieves, prostate cancer tumors scavenge ... the body. But such avarice may be a fatal ... a way to kill prostate cancer cells by delivering ... selectively destroys the diseased cells brimming with the mineral, ... uses two drugs already commercially available for other uses, ...
    Breaking Biology News(10 mins):Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Prostate cancer's penchant for copper may be a fatal flaw 2
    ... Rainmakers, Inc., an intellectual property holding company and advanced ... its "stealth" mode and is prepared to actively commercialize ... security offerings. , During the past four years, the ... develop and deploy a series of core--but expandable--technologies built ...
    ... up 45 percent of blood, normally take the shape of ... can sometimes deform into an asymmetrical slipper shape. A ... flow might be responsible for this deformation, as well as ... could help understand the mechanisms involved in arterial disease and ...
    ... CAMDEN Contrary to a national trend, more and ... major in math and science. Thanks to a $307,277 ... students in the sciences at RutgersCamden will receive unprecedented ... of their degrees. Through a new RutgersCamden program ...
    Cached Biology News:Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 2Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 3NSF grant supports Rutgers-Camden program for science majors 2NSF grant supports Rutgers-Camden program for science majors 3
    Hucal Agx Antigen Expression Service Specificity: Hucal Agx ...
    MHC. Sections include: the isolation and functional properties of antigen-presenting cells analysis of MHC class II endocytosis and peptide turnover analysis of signalling via MHC class II molecu...
    ... PAGE Cleavable ICAT Reagent ... Protein ID and Quantitation ... Electrophoresis (PAGE), isotope-coded affinity ... technology to facilitate the ...
    Supplemental reagent for annexin V assay....
    Biology Products: